Cargando…
Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist
Introduction: Orchidectomy is currently the preferred method to induce bone loss in preclinical male osteoporosis model. Gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer treatment can induce testosterone deficiency but its effects on bone in preclinical male osteoporosis model...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835701/ https://www.ncbi.nlm.nih.gov/pubmed/29511366 http://dx.doi.org/10.7150/ijms.22732 |
_version_ | 1783303850518642688 |
---|---|
author | Mohamad, Nur-Vaizura Che Zulkepli, Muhammad Afiq Amani May Theseira, Krystine Zulkifli, Norain Shahrom, Nur Quraisha Ridzuan, Nurul Amni Mohamad Jamil, Nor Aini Soelaiman, Ima-Nirwana Chin, Kok-Yong |
author_facet | Mohamad, Nur-Vaizura Che Zulkepli, Muhammad Afiq Amani May Theseira, Krystine Zulkifli, Norain Shahrom, Nur Quraisha Ridzuan, Nurul Amni Mohamad Jamil, Nor Aini Soelaiman, Ima-Nirwana Chin, Kok-Yong |
author_sort | Mohamad, Nur-Vaizura |
collection | PubMed |
description | Introduction: Orchidectomy is currently the preferred method to induce bone loss in preclinical male osteoporosis model. Gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer treatment can induce testosterone deficiency but its effects on bone in preclinical male osteoporosis model are less studied. Objective: This study aimed to evaluate the skeletal effect of buserelin (a GnRH agonist) in male rats and compare it with orchidectomy. Methods: Forty-six three-month-old male Sprague-Dawley rats were divided into three experimental arms. The baseline arm (n=6) was sacrificed at the onset of the study. In the buserelin arm, the rats received a daily subcutaneous injection of either normal saline (n=8), buserelin acetate at 25 µg/kg (n=8) or 75 µg/kg (n=8). In the orchidectomy arm, the rats were either sham-operated (n=8) or orchidectomized (n=8). All groups underwent in-vivo X-ray micro-computed tomography scanning at the left proximal tibia every month. Blood was collected at the beginning and the end of the study for testosterone level evaluation. The rats were euthanized after the three-month treatment. The femurs were harvested for biomechanical strength and bone calcium determination. Results: The results showed that buserelin at both doses caused a significant decline in testosterone level and deterioration in bone microstructure (p<0.05), but did not affect bone calcium content (p>0.05). Buserelin at 25 µg/kg decreased displacement and strain of the femur significantly (p<0.05). Similar changes were observed in the orchidectomized group compared to the sham-operated group but without any significant changes in biomechanical strength (p>0.05). Conclusion: Buserelin can induce testosterone deficiency and the associated deterioration of bone microarchitecture similar to orchidectomy in three months. However, it may require a longer time to show significant effects on bone strength and mineral content. |
format | Online Article Text |
id | pubmed-5835701 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-58357012018-03-06 Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist Mohamad, Nur-Vaizura Che Zulkepli, Muhammad Afiq Amani May Theseira, Krystine Zulkifli, Norain Shahrom, Nur Quraisha Ridzuan, Nurul Amni Mohamad Jamil, Nor Aini Soelaiman, Ima-Nirwana Chin, Kok-Yong Int J Med Sci Research Paper Introduction: Orchidectomy is currently the preferred method to induce bone loss in preclinical male osteoporosis model. Gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer treatment can induce testosterone deficiency but its effects on bone in preclinical male osteoporosis model are less studied. Objective: This study aimed to evaluate the skeletal effect of buserelin (a GnRH agonist) in male rats and compare it with orchidectomy. Methods: Forty-six three-month-old male Sprague-Dawley rats were divided into three experimental arms. The baseline arm (n=6) was sacrificed at the onset of the study. In the buserelin arm, the rats received a daily subcutaneous injection of either normal saline (n=8), buserelin acetate at 25 µg/kg (n=8) or 75 µg/kg (n=8). In the orchidectomy arm, the rats were either sham-operated (n=8) or orchidectomized (n=8). All groups underwent in-vivo X-ray micro-computed tomography scanning at the left proximal tibia every month. Blood was collected at the beginning and the end of the study for testosterone level evaluation. The rats were euthanized after the three-month treatment. The femurs were harvested for biomechanical strength and bone calcium determination. Results: The results showed that buserelin at both doses caused a significant decline in testosterone level and deterioration in bone microstructure (p<0.05), but did not affect bone calcium content (p>0.05). Buserelin at 25 µg/kg decreased displacement and strain of the femur significantly (p<0.05). Similar changes were observed in the orchidectomized group compared to the sham-operated group but without any significant changes in biomechanical strength (p>0.05). Conclusion: Buserelin can induce testosterone deficiency and the associated deterioration of bone microarchitecture similar to orchidectomy in three months. However, it may require a longer time to show significant effects on bone strength and mineral content. Ivyspring International Publisher 2018-01-19 /pmc/articles/PMC5835701/ /pubmed/29511366 http://dx.doi.org/10.7150/ijms.22732 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Mohamad, Nur-Vaizura Che Zulkepli, Muhammad Afiq Amani May Theseira, Krystine Zulkifli, Norain Shahrom, Nur Quraisha Ridzuan, Nurul Amni Mohamad Jamil, Nor Aini Soelaiman, Ima-Nirwana Chin, Kok-Yong Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist |
title | Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist |
title_full | Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist |
title_fullStr | Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist |
title_full_unstemmed | Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist |
title_short | Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist |
title_sort | establishing an animal model of secondary osteoporosis by using a gonadotropin-releasing hormone agonist |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835701/ https://www.ncbi.nlm.nih.gov/pubmed/29511366 http://dx.doi.org/10.7150/ijms.22732 |
work_keys_str_mv | AT mohamadnurvaizura establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist AT chezulkeplimuhammadafiqamani establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist AT maytheseirakrystine establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist AT zulkiflinorain establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist AT shahromnurquraisha establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist AT ridzuannurulamnimohamad establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist AT jamilnoraini establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist AT soelaimanimanirwana establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist AT chinkokyong establishingananimalmodelofsecondaryosteoporosisbyusingagonadotropinreleasinghormoneagonist |